VC-backed AbCellera buys Dualogics' bispecific platform

AbCellera, a Vancouver, British Columbia-based developer of therapeutic antibodies, has acquired the OrthoMab bispecific platform of Dualogics.

20 August 2020•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.